Walmsley Under Pressure Over GSK’s Strategy

Activist Investor Preparing To Pounce

GSK’s share price is down by 15% since Walmsley took over as CEO, but major investors are said to be resisting calls for a radical re-think in its strategy.

GSK HQ
Investors remain unimpressed with GSK's turnaround efforts - but support for Elliott's rebellion is likely to be limited.

GlaxoSmithKline’s chief executive Dame Emma Walmsley is under increasing pressure from investors to prove her strategy for the business will pay off in the next few years.

Walmsley took the helm in 2017, and the spin-off of its consumer health division (a joint venture with Pfizer) is...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip